This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ando, Y. Articles by Figg, W. D. Search for Related Content PubMed PubMed Citation Articles by Ando, Y. Articles by Figg, W. D.

Thalidomide Metabolism by the CYP2C Subfamily¹

Molecular Pharmacology Section, Cancer Therapeutic Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892

Purpose: This research investigated the biotransformation of thalidomide by cytochrome P-450 (CYP).

Experimental Design: We used liver microsomes from humans and/or animals and the recombinant specific CYP isozymes to investigate CYP-mediated metabolism of thalidomide.

Results: Thalidomide was biotransformed into 5-hydroxythalidomide (5-OH) and diastereomeric 5'-hydroxythalidomide (5'-OH) by liver microsomes. The human liver microsomes with higher CYP2C19 activity formed more metabolites than those with lower CYP2C19 activity and had less activity in metabolite formations than those from rats. Recombinant human CYP2C19 and rat CYP2C6 isozymes were primarily responsible for forming these metabolites, and the male rat-specific CYP2C11 formed only 5'-OH. 5-OH was subsequently hydroxylated to 5,6-dihydroxythalidomide by CYP2C19, CYP2C9, and CYP1A1 in humans and by CYP2C11, CYP1A1, CYP2C6, and CYP2C12 in rats. Incubations with S-mephenytoin and omeprazole, substrates of CYP2C19, inhibited metabolism by human liver microsomes, supporting the involvement of CYP2C19. -Naphthoflavone, an inhibitor of CYP1A, simultaneously stimulated the 5-OH formation and inhibited cis-5'-OH formation catalyzed by human liver microsomes. The contribution of the CYP2C subfamily was supported by the immunoinhibition study using human liver microsomes. When we used the microsomes from treated rats, the metabolite formations did not increase by inducers for CYP1A, CYP2B, CYP2E, CYP3A, or CYP4A, suggesting that these could not be involved in the main metabolic pathway in rats.

Conclusions: We discovered that the polymorphic enzyme CYP2C19 is responsible for 5- and 5'-hydroxylation of thalidomide in humans. In rats, thalidomide was hydroxylated extensively by CYP2C6 as well as the sex-specific enzyme CYP2C11.

This article has been cited by other articles:

				Z. Desta, A. Modak, P. D. Nguyen, S. M. Lemler, Y. Kurogi, L. Li, and D. A. Flockhart Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 297 - 305. [Abstract] [Full Text] [PDF]

				Y. Okada, N. Murayama, C. Yanagida, M. Shimizu, F. P. Guengerich, and H. Yamazaki Drug Interactions of Thalidomide with Midazolam and Cyclosporine A: Heterotropic Cooperativity of Human Cytochrome P450 3A5 Drug Metab. Dispos., January 1, 2009; 37(1): 18 - 23. [Abstract] [Full Text] [PDF]

				Y. Li, J. Hou, H. Jiang, D. Wang, W. Fu, Z. Yuan, Y. Chen, and L. Zhou Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma Haematologica, September 1, 2007; 92(9): 1246 - 1249. [Abstract] [Full Text] [PDF]

				X.-X. Yang, Z.-P. Hu, A.-L. Xu, W. Duan, Y.-Z. Zhu, M. Huang, F.-S. Sheu, Q. Zhang, J.-S. Bian, E. Chan, et al. A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor-{alpha} Inhibitor J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 82 - 104. [Abstract] [Full Text] [PDF]

				N. A. Warfel, E. R. Lepper, C. Zhang, W. D. Figg, and P. A. Dennis Importance of the Stress Kinase p38{alpha} in Mediating the Direct Cytotoxic Effects of the Thalidomide Analogue, CPS49, in Cancer Cells and Endothelial Cells. Clin. Cancer Res., June 1, 2006; 12(11): 3502 - 3509. [Abstract] [Full Text] [PDF]

				M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]

				F. Chung, J. Lu, B. D. Palmer, P. Kestell, P. Browett, B. C. Baguley, M. Tingle, and L.-M. Ching Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients Clin. Cancer Res., September 1, 2004; 10(17): 5949 - 5956. [Abstract] [Full Text] [PDF]

				J. Lu, N. Helsby, B. D. Palmer, M. Tingle, B. C. Baguley, P. Kestell, and L.-M. Ching Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 571 - 577. [Abstract] [Full Text] [PDF]

				S. Zhou Correspondence re: J. Lu et al., Thalidomide Metabolites in Mice and Patients with Multiple Myeloma. Clin. Cancer Res., 9: 1680-1688, 2003. Clin. Cancer Res., November 1, 2003; 9(14): 5429 - 5429. [Full Text] [PDF]

				E. J. Giamarellos-Bourboulis, H. Poulaki, N. Kostomitsopoulos, I. Dontas, D. Perrea, P. E. Karayannacos, and H. Giamarellou Effective Immunomodulatory Treatment of Escherichia coli Experimental Sepsis with Thalidomide Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2445 - 2449. [Abstract] [Full Text] [PDF]

				S. Zhou CYP1A1-MEDIATED ACTIVATION OF THALIDOMIDE AND SUPPRESSION OF EMBRYO FIBROBLAST PROLIFERATION Drug Metab. Dispos., August 1, 2003; 31(8): 1072 - 1072. [Full Text] [PDF]

				S. S. W. Ng, M. Gutschow, M. Weiss, S. Hauschildt, U. Teubert, T. K. Hecker, F. A. Luzzio, E. A. Kruger, K. Eger, and W. D. Figg Antiangiogenic Activity of N-substituted and Tetrafluorinated Thalidomide Analogues Cancer Res., June 15, 2003; 63(12): 3189 - 3194. [Abstract] [Full Text] [PDF]

				J. Lu, B. D. Palmer, P. Kestell, P. Browett, B. C. Baguley, G. Muller, and L.-M. Ching Thalidomide Metabolites in Mice and Patients with Multiple Myeloma Clin. Cancer Res., May 1, 2003; 9(5): 1680 - 1688. [Abstract] [Full Text] [PDF]

				M. Miyata, E. Tamura, K. Motoki, K. Nagata, and Y. Yamazoe Thalidomide-induced Suppression of Embryo Fibroblast Proliferation Requires CYP1A1-Mediated Activation Drug Metab. Dispos., April 1, 2003; 31(4): 469 - 475. [Abstract] [Full Text] [PDF]